OCX vs. DRRX, CDIO, AWH, TRIB, ACHL, BMRA, ICCC, ABIO, VNRX, and IFRX
Should you be buying OncoCyte stock or one of its competitors? The main competitors of OncoCyte include DURECT (DRRX), Cardio Diagnostics (CDIO), Aspira Women's Health (AWH), Trinity Biotech (TRIB), Achilles Therapeutics (ACHL), Biomerica (BMRA), ImmuCell (ICCC), ARCA biopharma (ABIO), VolitionRx (VNRX), and InflaRx (IFRX). These companies are all part of the "medical" sector.
DURECT (NASDAQ:DRRX) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, community ranking, media sentiment, risk, profitability and institutional ownership.
DURECT currently has a consensus price target of $27.50, suggesting a potential upside of 2,825.22%. OncoCyte has a consensus price target of $4.06, suggesting a potential upside of 37.25%. Given OncoCyte's stronger consensus rating and higher possible upside, analysts plainly believe DURECT is more favorable than OncoCyte.
DURECT has a net margin of -279.77% compared to DURECT's net margin of -2,905.14%. DURECT's return on equity of -135.45% beat OncoCyte's return on equity.
DURECT has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, OncoCyte has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.
DURECT received 310 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 65.56% of users gave DURECT an outperform vote while only 9.23% of users gave OncoCyte an outperform vote.
28.0% of DURECT shares are held by institutional investors. Comparatively, 55.4% of OncoCyte shares are held by institutional investors. 4.3% of DURECT shares are held by company insiders. Comparatively, 1.9% of OncoCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
DURECT has higher revenue and earnings than OncoCyte.
In the previous week, DURECT had 8 more articles in the media than OncoCyte. MarketBeat recorded 19 mentions for DURECT and 11 mentions for OncoCyte. OncoCyte's average media sentiment score of 0.34 beat DURECT's score of -0.03 indicating that DURECT is being referred to more favorably in the media.
Summary
DURECT beats OncoCyte on 12 of the 16 factors compared between the two stocks.
Get OncoCyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OncoCyte Competitors List
Related Companies and Tools
